Armio Reetta-Liina, Laurikainen Heikki, Ilonen Tuula, Walta Maija, Sormunen Elina, Tolvanen Arvi, Salokangas Raimo K R, Koutsouleris Nikolaos, Tuominen Lauri, Hietala Jarmo
PET Centre, Turku University Hospital, 20520, Turku, Finland.
Department of Psychiatry, University of Turku, 20700, Turku, Finland.
Schizophrenia (Heidelb). 2024 Jul 31;10(1):66. doi: 10.1038/s41537-024-00475-z.
Altered hippocampal morphology and metabolic pathology, but also hippocampal circuit dysfunction, are established phenomena seen in psychotic disorders. Thus, we tested whether hippocampal subfield volume deficits link with deviations in glucose metabolism commonly seen in early psychosis, and whether the glucose parameters or subfield volumes change during follow-up period using one-year longitudinal study design of 78 first-episode psychosis patients (FEP), 48 clinical high-risk patients (CHR) and 83 controls (CTR). We also tested whether hippocampal morphology and glucose metabolism relate to clinical outcome. Hippocampus subfields were segmented with Freesurfer from 3T MRI images and parameters of glucose metabolism were determined in fasting plasma samples. Hippocampal subfield volumes were consistently lower in FEPs, and findings were more robust in non-affective psychoses, with strongest decreases in CA1, molecular layer and hippocampal tail, and in hippocampal tail of CHRs, compared to CTRs. These morphometric differences remained stable at one-year follow-up. Both non-diabetic CHRs and FEPs had worse glucose parameters compared to CTRs at baseline. We found that, insulin levels and insulin resistance increased during the follow-up period only in CHR, effect being largest in the CHRs converting to psychosis, independent of exposure to antipsychotics. The worsening of insulin resistance was associated with deterioration of function and symptoms in CHR. The smaller volume of hippocampal tail was associated with higher plasma insulin and insulin resistance in FEPs, at the one-year follow-up. Our longitudinal study supports the view that temporospatial hippocampal subfield volume deficits are stable near the onset of first psychosis, being more robust in non-affective psychoses, but less prominent in the CHR group. Specific subfield defects were related to worsening glucose metabolism during the progression of psychosis, suggesting that hippocampus is part of the circuits regulating aberrant glucose metabolism in early psychosis. Worsening of glucose metabolism in CHR group was associated with worse clinical outcome measures indicating a need for heightened clinical attention to metabolic problems already in CHR.
海马体形态和代谢病理的改变,以及海马体回路功能障碍,是在精神障碍中已被证实的现象。因此,我们采用一项针对78例首发精神病患者(FEP)、48例临床高危患者(CHR)和83例对照者(CTR)的为期一年的纵向研究设计,测试海马体亚区体积缺陷是否与早期精神病中常见的葡萄糖代谢偏差相关,以及在随访期间葡萄糖参数或亚区体积是否发生变化。我们还测试了海马体形态和葡萄糖代谢是否与临床结局相关。利用Freesurfer软件从3T磁共振成像(MRI)图像中分割出海马体亚区,并在空腹血浆样本中测定葡萄糖代谢参数。与CTR相比,FEP的海马体亚区体积始终较小,且在非情感性精神病中这一发现更为显著,CA1、分子层和海马尾部以及CHR的海马尾部体积减少最为明显。这些形态学差异在一年的随访中保持稳定。在基线时,与CTR相比,非糖尿病的CHR和FEP的葡萄糖参数更差。我们发现,仅在CHR中,随访期间胰岛素水平和胰岛素抵抗增加,在转化为精神病的CHR中影响最大,且与抗精神病药物的使用无关。胰岛素抵抗的恶化与CHR的功能和症状恶化相关。在一年的随访中,FEP中海马尾部体积较小与血浆胰岛素水平升高和胰岛素抵抗相关。我们的纵向研究支持这样一种观点,即颞叶海马体亚区体积缺陷在首次精神病发作时较为稳定,在非情感性精神病中更为显著,但在CHR组中不太突出。特定的亚区缺陷与精神病进展过程中葡萄糖代谢恶化相关,这表明海马体是调节早期精神病中异常葡萄糖代谢的回路的一部分。CHR组葡萄糖代谢恶化与更差的临床结局指标相关,这表明在CHR中就需要对代谢问题给予更高的临床关注。